Cannabis for Acute Migraine
(2026)Objective
To assess the efficacy of vaporized cannabis (THC-dominant, CBD-dominant, and combined THC+CBD) versus placebo cannabis flower for the acute treatment of migraine attacks, as no prior randomized controlled trial had examined cannabinoids for acute migraine.
Study Summary
• THC-dominant (6% THC) was superior to placebo for 2-h pain relief (68.9% vs 46.6%; OR 3.14 [1.35–7.30], p=0.008) but NOT for pain freedom or MBS freedom.
• CBD-dominant (11% CBD) was not superior to placebo for any endpoint.
• There were no serious adverse events.
Intervention
Vaporized cannabis flower self-administered via standardized 4-puff Foltin Uniform Puff Procedure at migraine onset, comparing 6% THC, 11% CBD, 6% THC + 11% CBD, and placebo flower.
Inclusion Criteria
Adults aged 21–65 with migraine per ICHD-3, 2–23 headache days and 2–23 migraine days per month, agreeing not to use cannabis (outside study drug), opioids, or barbiturates.
Study Design
Arms: THC-dominant 6% THC (n=63) vs CBD-dominant 11% CBD (n=60) vs THC+CBD 6%+11% (n=60) vs Placebo cannabis flower (n=64)
Patients per Arm: 92 participants randomized; 247 migraine attacks treated (THC 63, CBD 60, THC+CBD 60, placebo 64)
Outcome
• THC+CBD achieved superior 2-h pain freedom (34.5% vs 15.5%) and MBS freedom (60.3% vs 34.5%) versus placebo, and was superior for freedom from photophobia and phonophobia (but not nausea/vomiting).
• Benefits with THC+CBD were sustained: pain freedom at 24 h, MBS freedom at 24 and 48 h.
• No serious adverse events.
Bottom Line
In the first RCT of cannabis for acute migraine, vaporized cannabis flower combining 6% THC + 11% CBD was superior to placebo for 2-h pain relief, pain freedom, and most-bothersome-symptom freedom, with benefits sustained to 48 h and no serious adverse events; THC alone helped pain relief but not pain freedom/MBS freedom, and CBD alone was ineffective.
Major Points
- First randomized controlled trial to evaluate vaporized cannabis for acute migraine treatment (2025 Wolff Award Winner).
- Combined THC + CBD (6% THC + 11% CBD) was superior to placebo across all three key endpoints at 2 h (pain relief, pain freedom, and MBS freedom), with sustained pain freedom at 24 h and sustained MBS freedom at 24 and 48 h.
- THC-dominant (6% THC) was superior to placebo for 2-h pain relief only; CBD-dominant (11% CBD) showed no benefit on any endpoint — suggesting the THC+CBD combination is the effective formulation.
- THC + CBD was superior to placebo for freedom from photophobia and phonophobia, but not nausea or vomiting.
- There were no serious adverse events.
Study Design
- Study Type
- Randomized, double-blind, placebo-controlled, 4-period crossover trial
- Randomization
- Yes
- Blinding
- Double-blind; participants, research coordinators, investigators, and statisticians blinded until completion of initial analysis — only research pharmacists were unblinded. Blinding effectiveness assessed with Bang's Blinding Index.
- Sample Size
- 92
- Follow-up
- Surveys at 1, 2, 24, and 48 h after each treated attack; ≥1 week (≥7 day) washout between treated attacks
- Centers
- 1
- Countries
- United States
Primary Outcome
Definition: 2-h pain relief (reduction of pain from moderate/severe to mild/none) — primary positive comparison THC + CBD vs placebo
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| Placebo 46.6% | THC + CBD 67.2% | 2.85 (1.22 to 6.65) | 0.016 |
Limitations & Criticisms
- Single-center trial conducted at one academic site (UCSD), limiting generalizability.
- Long-term effects of frequent cannabis use were not examined.
- NIDA Drug Supply Program cannabis potencies were lower than typical recreational/dispensary products, which may limit applicability to commonly available products.
- Blinding is inherently challenging with psychoactive THC; blinding index (Bang's BI) was assessed to address this.
- Predominantly female population (83%).
Citation
Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L, Sexton M. Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. Headache. 2026;66:365–376.